These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32246062)

  • 1. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
    Spiegelberg D; Abramenkovs A; Mortensen ACL; Lundsten S; Nestor M; Stenerlöw B
    Sci Rep; 2020 Apr; 10(1):5923. PubMed ID: 32246062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
    Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
    Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
    [No Abstract]   [Full Text] [Related]  

  • 3. The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.
    Lundsten S; Spiegelberg D; Stenerlöw B; Nestor M
    Int J Oncol; 2019 Dec; 55(6):1287-1295. PubMed ID: 31638190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
    Naz S; Leiker AJ; Choudhuri R; Preston O; Sowers AL; Gohain S; Gamson J; Mathias A; Van Waes C; Cook JA; Mitchell JB
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1295-1305. PubMed ID: 33838214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
    Xu J; Wu PJ; Lai TH; Sharma P; Canella A; Welker AM; Beattie CE; Elder JB; Easley M; Lonser R; Jacob NK; Pietrzak M; Timmers CM; Lang F; Sampath D; Puduvalli VK
    Clin Cancer Res; 2022 May; 28(9):1979-1990. PubMed ID: 35140124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.
    Spiegelberg D; Dascalu A; Mortensen AC; Abramenkovs A; Kuku G; Nestor M; Stenerlöw B
    Oncotarget; 2015 Nov; 6(34):35652-66. PubMed ID: 26452257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts.
    Mehta RK; Pal S; Kondapi K; Sitto M; Dewar C; Devasia T; Schipper MJ; Thomas DG; Basrur V; Pai MP; Morishima Y; Osawa Y; Pratt WB; Lawrence TS; Nyati MK
    Clin Cancer Res; 2020 Oct; 26(19):5246-5257. PubMed ID: 32718999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
    Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
    Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
    Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition.
    Gomez-Casal R; Epperly MW; Wang H; Proia DA; Greenberger JS; Levina V
    Oncotarget; 2015 Dec; 6(42):44306-22. PubMed ID: 26517240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer.
    Jansson KH; Tucker JB; Stahl LE; Simmons JK; Fuller C; Beshiri ML; Agarwal S; Fang L; Hynes PG; Alilin AN; Lake R; Abbey YC; Cawley J; Tice CM; Yin J; McKnight C; Klummp-Thomas C; Zhang X; Guha R; Hoover S; Simpson RM; Nguyen HM; Corey E; Thomas CJ; Proia DA; Kelly K
    Sci Rep; 2018 Nov; 8(1):17239. PubMed ID: 30467317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.
    Lai TH; Mitchell S; Wu PJ; Orwick S; Liu C; Ravikrishnan J; Woyach J; Mims A; Plunkett W; Puduvalli VK; Byrd JC; Lapalombella R; Sampath D
    Leuk Lymphoma; 2019 Sep; 60(9):2308-2311. PubMed ID: 30773117
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.
    Do K; Speranza G; Chang LC; Polley EC; Bishop R; Zhu W; Trepel JB; Lee S; Lee MJ; Kinders RJ; Phillips L; Collins J; Lyons J; Jeong W; Antony R; Chen AP; Neckers L; Doroshow JH; Kummar S
    Invest New Drugs; 2015 Aug; 33(4):921-30. PubMed ID: 26082332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
    Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.
    Courtin A; Smyth T; Hearn K; Saini HK; Thompson NT; Lyons JF; Wallis NG
    Br J Cancer; 2016 Oct; 115(9):1069-1077. PubMed ID: 27673365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.
    Kinzel L; Ernst A; Orth M; Albrecht V; Hennel R; Brix N; Frey B; Gaipl US; Zuchtriegel G; Reichel CA; Blutke A; Schilling D; Multhoff G; Li M; Niyazi M; Friedl AA; Winssinger N; Belka C; Lauber K
    Oncotarget; 2016 Jul; 7(28):43199-43219. PubMed ID: 27259245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.
    Lee Y; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
    Mol Cancer Ther; 2017 Jan; 16(1):16-24. PubMed ID: 28062703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.
    Mortensen ACL; Mohajershojai T; Hariri M; Pettersson M; Spiegelberg D
    Front Oncol; 2020; 10():532285. PubMed ID: 33102211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 inhibitors diminish PDGF-BB-induced migration of osteoblasts via suppression of p44/p42 MAP kinase.
    Kawabata T; Tokuda H; Fujita K; Matsushima-Nishiwaki R; Sakai G; Tachi J; Hioki T; Kim W; Iida H; Otsuka T; Kozawa O
    Biomed Res; 2019; 40(4):169-178. PubMed ID: 31413238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.
    Slovin S; Hussain S; Saad F; Garcia J; Picus J; Ferraldeschi R; Crespo M; Flohr P; Riisnaes R; Lin C; Keer H; Oganesian A; Workman P; de Bono J
    Clin Cancer Res; 2019 Aug; 25(15):4624-4633. PubMed ID: 31113841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.